ijms-logo

Journal Browser

Journal Browser

Special Issue "Novel Approaches to Hematologic Malignancies by Immunotherapy"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 September 2020).

Special Issue Editor

Dr. Yosuke Minami
Website
Guest Editor
National Cancer Center Hospital East, Kashiwa, Japan
Interests: leukemia; molecular target therapy; immunotherapy

Special Issue Information

Dear Colleagues,

The landscape of immunotherapy for the treatment hematogic malignancies (HMs) has become crowded in light of new modalities. Some HMs can escape T-cell-mediated cellular cytotoxicity by exloiting the inhibitory programmed cell-death protein 1 (PD-1)/ programmed cell-death protein 1 ligand 1 (PD-L1) immune checkpoint. Therapeutic antibodies that block the PD-1-PD-L1 axis or other types of checkpoint inhibitors induce durable clinical responses against a growing list of various HMs. Chimeric antigen receptor (CAR) T cells, bispecific T-cell engagers (BiTEs), and antibody-drug conjugates (ADCs) are also promising candidates. In this issue, we would like to show the novel immunotherapy in translational research and clinical development for the treatment of HMs.

Dr. Yosuke Minami
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Hematologic malignancies
  • immunotherapy
  • programmed cell-death protein 1 (PD-1)
  • Chimeric antigen receptor (CAR) T
  • bispecific T-cell engagers (BiTEs)
  • checkpoint inhibitor
  • antibody-drug conjugates (ADCs)

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Open AccessReview
Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
Int. J. Mol. Sci. 2020, 21(21), 8000; https://doi.org/10.3390/ijms21218000 (registering DOI) - 27 Oct 2020
Abstract
Immunotherapy is extensively investigated for almost all types of hematologic tumors, from preleukemic to relapse/refractory malignancies. Due to the emergence of technologies for target cell characterization, antibody design and manufacturing, as well as genome editing, immunotherapies including gene and cell therapies are becoming [...] Read more.
Immunotherapy is extensively investigated for almost all types of hematologic tumors, from preleukemic to relapse/refractory malignancies. Due to the emergence of technologies for target cell characterization, antibody design and manufacturing, as well as genome editing, immunotherapies including gene and cell therapies are becoming increasingly elaborate and diversified. Understanding the tumor immune microenvironment of the target disease is critical, as is reducing toxicity. Although there have been many successes and newly FDA-approved immunotherapies for hematologic malignancies, we have learned that insufficient efficacy due to disease relapse following treatment is one of the key obstacles for developing successful therapeutic regimens. Thus, combination therapies are also being explored. In this review, immunotherapies for each type of hematologic malignancy will be introduced, and novel targets that are under investigation will be described. Full article
(This article belongs to the Special Issue Novel Approaches to Hematologic Malignancies by Immunotherapy)
Show Figures

Figure 1

Open AccessReview
Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia
Int. J. Mol. Sci. 2020, 21(20), 7685; https://doi.org/10.3390/ijms21207685 - 16 Oct 2020
Abstract
T-cell acute lymphoblastic leukemia (T-ALL), a T-cell malignant disease that mainly affects children, is still a medical challenge, especially for refractory patients for whom therapeutic options are scarce. Recent advances in immunotherapy for B-cell malignancies based on increasingly efficacious monoclonal antibodies (mAbs) and [...] Read more.
T-cell acute lymphoblastic leukemia (T-ALL), a T-cell malignant disease that mainly affects children, is still a medical challenge, especially for refractory patients for whom therapeutic options are scarce. Recent advances in immunotherapy for B-cell malignancies based on increasingly efficacious monoclonal antibodies (mAbs) and chimeric antigen receptors (CARs) have been encouraging for non-responding or relapsing patients suffering from other aggressive cancers like T-ALL. However, secondary life-threatening T-cell immunodeficiency due to shared expression of targeted antigens by healthy and malignant T cells is a main drawback of mAb—or CAR-based immunotherapies for T-ALL and other T-cell malignancies. This review provides a comprehensive update on the different immunotherapeutic strategies that are being currently applied to T-ALL. We highlight recent progress on the identification of new potential targets showing promising preclinical results and discuss current challenges and opportunities for developing novel safe and efficacious immunotherapies for T-ALL. Full article
(This article belongs to the Special Issue Novel Approaches to Hematologic Malignancies by Immunotherapy)
Show Figures

Figure 1

Open AccessReview
Immune-Checkpoint Blockade Therapy in Lymphoma
Int. J. Mol. Sci. 2020, 21(15), 5456; https://doi.org/10.3390/ijms21155456 - 30 Jul 2020
Abstract
Tumor cells use immune-checkpoint pathways to evade the host immune system and suppress immune cell function. These cells express programmed cell-death protein 1 ligand 1 (PD-L1)/PD-L2, which bind to the programmed cell-death protein 1 (PD-1) present on cytotoxic T cells, trigger inhibitory signaling, [...] Read more.
Tumor cells use immune-checkpoint pathways to evade the host immune system and suppress immune cell function. These cells express programmed cell-death protein 1 ligand 1 (PD-L1)/PD-L2, which bind to the programmed cell-death protein 1 (PD-1) present on cytotoxic T cells, trigger inhibitory signaling, and reduce cytotoxicity and T-cell exhaustion. Immune-checkpoint blockade can inhibit this signal and may serve as an effective therapeutic strategy in patients with solid tumors. Several trials have been conducted on immune-checkpoint inhibitor therapy in patients with malignant lymphoma and their efficacy has been reported. For example, in Hodgkin lymphoma, immune-checkpoint blockade has resulted in response rates of 65% to 75%. However, in non-Hodgkin lymphoma, the response rate to immune-checkpoint blockade was lower. In this review, we evaluate the biology of immune-checkpoint inhibition and the current data on its efficacy in malignant lymphoma, and identify the cases in which the treatment was more effective. Full article
(This article belongs to the Special Issue Novel Approaches to Hematologic Malignancies by Immunotherapy)
Back to TopTop